PL3458074T3 - KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA - Google Patents

KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA

Info

Publication number
PL3458074T3
PL3458074T3 PL17800042.8T PL17800042T PL3458074T3 PL 3458074 T3 PL3458074 T3 PL 3458074T3 PL 17800042 T PL17800042 T PL 17800042T PL 3458074 T3 PL3458074 T3 PL 3458074T3
Authority
PL
Poland
Prior art keywords
trna
nanoparticles
delivery
compositions
methods
Prior art date
Application number
PL17800042.8T
Other languages
English (en)
Inventor
Philip J. Thomas
Daniel J. Siegwart
Arthur E. Johnson
Michael J. Torres
Jason B. Miller
Original Assignee
Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents Of The University Of Texas System filed Critical Board Of Regents Of The University Of Texas System
Publication of PL3458074T3 publication Critical patent/PL3458074T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17800042.8T 2016-05-16 2017-05-16 KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA PL3458074T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662337096P 2016-05-16 2016-05-16
PCT/US2017/032967 WO2017201091A1 (en) 2016-05-16 2017-05-16 COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH

Publications (1)

Publication Number Publication Date
PL3458074T3 true PL3458074T3 (pl) 2024-11-12

Family

ID=60326616

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17800042.8T PL3458074T3 (pl) 2016-05-16 2017-05-16 KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA

Country Status (11)

Country Link
US (2) US20170354672A1 (pl)
EP (2) EP4393549A3 (pl)
JP (3) JP7312552B2 (pl)
CN (2) CN109414451B (pl)
AU (3) AU2017268272C1 (pl)
CA (1) CA3024135C (pl)
DK (1) DK3458074T3 (pl)
ES (1) ES2985317T3 (pl)
PL (1) PL3458074T3 (pl)
PT (1) PT3458074T (pl)
WO (1) WO2017201091A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11247968B2 (en) * 2015-09-14 2022-02-15 The Board Of Regents Of The University Of Texas System Lipocationic dendrimers and uses thereof
EP3589751A4 (en) 2017-03-03 2021-11-17 The Regents of The University of California RNA TARGETING OF MUTATIONS VIA SUPPRESSOR RNA AND DEAMINASES
KR102857378B1 (ko) 2017-11-02 2025-09-11 유니버시티 오브 아이오와 리써치 파운데이션 ACE-tRNA에 의한 유전자 재지정을 통해 정지 코돈을 구조하는 방법
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
GB2592505B (en) 2018-09-04 2023-05-03 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
WO2020051220A1 (en) 2018-09-04 2020-03-12 The Board of the Regents of the University of Texas System Compositions and methods for organ specific delivery of nucleic acids
CN109266734A (zh) * 2018-09-25 2019-01-25 深圳市人民医院 自身免疫性疾病诊断试剂盒和应用
US10905778B2 (en) 2018-09-26 2021-02-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder
CA3114108A1 (en) * 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder
WO2020069199A1 (en) * 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder
WO2020243560A1 (en) * 2019-05-31 2020-12-03 Flagship Pioneering, Inc. Uses of trem compositions to modulate trna pools
CN115038789A (zh) 2019-12-02 2022-09-09 塑造治疗公司 治疗性编辑
WO2021252354A1 (en) * 2020-06-12 2021-12-16 University Of Rochester ENCODING AND EXPRESSION OF ACE-tRNAs
WO2022204219A1 (en) 2021-03-22 2022-09-29 Recode Therapeutics, Inc. Compositions and methods for targeted delivery to cells
JP2024511437A (ja) 2021-03-23 2024-03-13 リコード セラピューティクス，インク． ポリヌクレオチド組成物、関連製剤、およびその使用方法
CN117881789A (zh) * 2021-06-09 2024-04-12 瑞科德治疗公司 多核苷酸组合物、相关制剂、及其使用方法
CN113416784A (zh) * 2021-07-18 2021-09-21 南京中医药大学 一种与乳腺癌诊断相关的血清外泌体tsRNA标志物及其应用
CA3257006A1 (en) * 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
WO2023218420A1 (en) 2022-05-13 2023-11-16 Janssen Pharmaceuticals, Inc. Mrna compositions for inducing latent hiv-1 reversal
CN115851911B (zh) * 2022-11-25 2025-10-24 南京鼓楼医院 一种用于鉴别狼疮性肾炎的尿液外泌体tsRNA标志物和探针及其应用
CN120693181A (zh) 2022-12-08 2025-09-23 瑞科德治疗公司 脂质纳米颗粒组合物及其用途
CN116515827B (zh) * 2023-03-20 2024-12-10 复旦大学附属眼耳鼻喉科医院 用于治疗年龄相关性黄斑变性的活性成分、药物组合物和应用
US12364773B2 (en) 2023-12-01 2025-07-22 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
WO2025137646A1 (en) 2023-12-22 2025-06-26 Recode Therapeutics, Inc. Gene editing methods and compositions for treating cystic fibrosis
CN117965718B (zh) * 2024-02-02 2024-09-06 江苏省中医院 一种与脓毒症相关的生物标志物及其应用
CN117771265B (zh) * 2024-02-23 2024-06-11 山东大学 一种用于延缓间充质干细胞衰老的小分子rna及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
EP1490489B1 (en) * 2002-03-14 2010-06-02 Commonwealth Scientific and Industrial Research Organisation Methods and means for monitoring and modulating gene silencing
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP2295570A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
BRPI0709603A2 (pt) * 2006-03-16 2011-07-19 Scripps Research Inst expressão de proteìnas geneticamente programada contendo o aminoácido não natural fenilselenocisteìna
CA2658768C (en) 2006-07-21 2016-05-17 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
WO2008045486A2 (en) * 2006-10-09 2008-04-17 The University Of North Carolina At Chapel Hill Nanoparticle compositions for controlled delivery of nucleic acids
CN101595215A (zh) * 2006-10-30 2009-12-02 普罗梅加公司 具有增强的动力学和功能性表达的突变水解酶蛋白
US20090253131A1 (en) * 2007-11-05 2009-10-08 Promega Corporation Hybrid fusion reporter and uses thereof
CN101910414B (zh) * 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
JP5777519B2 (ja) * 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
KR100909786B1 (ko) * 2008-11-10 2009-07-29 고려대학교 산학협력단 올리고 펩티드를 수식한 신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는 전달체
EP2437756A2 (en) 2009-06-02 2012-04-11 Wu, Nian Pure peg-lipid conjugates
CN101591428B (zh) 2009-06-29 2011-05-25 浙江大学 一种聚酯树枝状大分子的制备方法
CA2765694C (en) * 2009-07-09 2021-05-18 Marina Biotech, Inc. Amphoteric liposomes comprising imino lipids
EP2496700B1 (en) * 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
KR101183989B1 (ko) * 2010-02-04 2012-09-19 전남대학교산학협력단 세포내 유전자 전달용 복합체, 이의 제조 방법 및 이를 이용한 세포내로의 유전자 전달 방법
AU2011281121A1 (en) * 2010-07-22 2013-02-21 Anima Cell Metrology, Inc. Systems and methods for detection of cellular stress
PL2694116T3 (pl) * 2011-04-06 2018-12-31 Board Of Regents Of The University Of Texas System Nanocząstki na bazie lipidów
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
AU2012267467B8 (en) 2011-06-08 2017-06-15 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
US20150031864A1 (en) * 2012-02-29 2015-01-29 Ambrx, Inc. Modified Adiponectin Polypeptides and Their Uses
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE DENDRIMER CONJUGATES AND ITS USES
KR20140048404A (ko) * 2012-10-11 2014-04-24 포항공과대학교 산학협력단 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물
WO2015011633A1 (en) * 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
CN103999853B (zh) 2014-06-11 2015-07-22 中国农业大学 荧光树枝状纳米大分子在制备药物载体中的应用
EP2966068A1 (en) 2014-07-08 2016-01-13 Incella GmbH Synthesis and use of amino lipids
CN104383596A (zh) * 2014-10-24 2015-03-04 东华大学 一种tpgs载药脂质体-天然材料复合纳米纤维支架的制备方法
AU2015360794B2 (en) 2014-12-08 2021-07-08 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
US11247968B2 (en) 2015-09-14 2022-02-15 The Board Of Regents Of The University Of Texas System Lipocationic dendrimers and uses thereof
EP3458032A4 (en) * 2016-05-16 2019-12-25 The Board of Regents of The University of Texas System CATIONIC SULFONAMIDE AMINOLIPIDS AND AMPHIPHILE ZWITTERIONIC AMINOLIPIDS

Also Published As

Publication number Publication date
CA3024135A1 (en) 2017-11-23
JP7789725B2 (ja) 2025-12-22
DK3458074T3 (da) 2024-07-29
JP7312552B2 (ja) 2023-07-21
CN109414451A (zh) 2019-03-01
EP4393549A3 (en) 2024-10-09
JP2023123863A (ja) 2023-09-05
CN115919769A (zh) 2023-04-07
US20210023120A1 (en) 2021-01-28
EP4393549A2 (en) 2024-07-03
WO2017201091A1 (en) 2017-11-23
AU2023226641B2 (en) 2025-06-26
AU2021225244B2 (en) 2023-09-28
EP3458074B1 (en) 2024-04-17
AU2023226641A1 (en) 2023-09-21
AU2021225244A1 (en) 2021-09-30
US20170354672A1 (en) 2017-12-14
AU2017268272C1 (en) 2022-05-05
BR112018073671A2 (pt) 2019-02-26
EP3458074A1 (en) 2019-03-27
CA3024135C (en) 2024-09-24
AU2017268272A1 (en) 2018-11-29
JP2026034537A (ja) 2026-02-27
PT3458074T (pt) 2024-08-21
JP2019515016A (ja) 2019-06-06
EP3458074A4 (en) 2020-01-22
CN109414451B (zh) 2022-08-12
ES2985317T3 (es) 2024-11-05
AU2017268272B2 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
PL3458074T3 (pl) KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
IL250744A0 (en) A method for preparing flavociclib and its pharmaceutical preparations
EP3355954A4 (en) METHODS AND COMPOSITIONS OF ADMINISTRATION
IL256621A (en) Carrier-binder preparations and methods for their preparation and use
IL252477A0 (en) 2-aminopyrimidine compound, pharmaceutical structure and its use
EP3194564A4 (en) Trichoderma compositions and methods of use
ZA202005857B (en) Oligonucleotide compositions and methods of making the same
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
IL259894A (en) Improved compositions and improved methods for viral delivery of neoepitopes and their use
EP3190886A4 (en) Compositions and methods of use thereof
EP3110422A4 (en) Compositions and methods for the delivery of therapeutics
PL3209828T3 (pl) Kompozycje włókniste zawierające n-halamine i ich zastosowanie
IL246587A0 (en) Preparations for use in the treatment of allergic conditions
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
EP3207029A4 (en) Tryptamide compositions and methods of use
GB201521306D0 (en) Compositions comprising nanoparticles and methods thereof
AU2014904383A0 (en) Compositions and methods for the delivery of agents that inhibit gene expression
AU2015904479A0 (en) Compositions and methods for the delivery of agents that inhibit gene expression
AU2014905067A0 (en) Compositions and methods of use
AU2014902829A0 (en) Compositions and Methods of Use